Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors
S Tettamanti, CF Magnani, A Biondi, E Biagi - Immunology letters, 2013 - Elsevier
In the context of acute myeloid leukemia (AML) treatment, the interface between
chemotherapy and immunotherapy is at present getting closer as never before. Scientific
research is oriented in overcoming the main limits of actual chemotherapeutic regimens
against AML, which still accounts for a considerable number of relapsed or resistant forms. A
lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently
gene-modified immune cells have been considered as an alternative approach whenever …
chemotherapy and immunotherapy is at present getting closer as never before. Scientific
research is oriented in overcoming the main limits of actual chemotherapeutic regimens
against AML, which still accounts for a considerable number of relapsed or resistant forms. A
lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently
gene-modified immune cells have been considered as an alternative approach whenever …